MetaVia Inc. (MTVA) Stock

MetaVia Inc. (MTVA) is a Healthcare stock trading at $1.47 (as of 2026-08-21), with a market capitalization of $9.65M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MetaVia Inc. is a clinical-stage biotechnology company developing and commercializing pharmaceutical candidates for cardiometabolic and related conditions. Its pipeline includes programs such as DA-1241 (GPR119 agonist) for metabolic dysfunction–associated steatohepatitis and prior work in type 2 diabetes, DA-1726 (oxyntomodulin analogue) for obesity, and other therapeutics including ANA001 for moderate COVID-19, plus NB-01/NB-02 and Gemcabene for dyslipidemia.

Valuation — source: SEC EDGAR (first-party)
Price$1.47
Market Cap$9.65M
Price / Book1.41
FCF Yield-112.3%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($169141.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOHeon Kim Hyung
Employees9
CountryUS
IPO Date2016-08-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • BioVie Inc. (BIVI)
  • Adial Pharmaceuticals, Inc. (ADIL)
  • Kiora Pharmaceuticals, Inc. (KPRX)
  • Aspire Biopharma Holdings, Inc. (ASBP)
  • Bullfrog AI Holdings, Inc. Common Stock (BFRG)
  • Theriva Biologics, Inc. (TOVX)
  • Imunon, Inc. (IMNN)
  • Traws Pharma, Inc. (TRAW)
MTVA earnings history · MTVA institutional & insider holders · MTVA KPIs & operating metrics · MTVA financials · MTVA investor presentations & press releases · MTVA SEC filings · MTVA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.